Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2013

01-04-2013 | Review Article

Clinical Strategies to Enhance the Efficacy of Nicotine Replacement Therapy for Smoking Cessation: A Review of the Literature

Authors: Matthew J. Carpenter, Bianca F. Jardin, Jessica L. Burris, Amanda R. Mathew, Robert A. Schnoll, Nancy A. Rigotti, K. Michael Cummings

Published in: Drugs | Issue 5/2013

Login to get access

Abstract

A number of smoking cessation pharmacotherapies have led to increases in quitting and thus to significant benefits to public health. Among existing medications, nicotine replacement therapy (NRT) has been available the longest, has the largest literature base in support, and is the only option for over-the-counter access. While the short-term efficacy of NRT is well documented in clinical trials, long-term abstinence rates associated with using NRT are modest, as most smokers will relapse. This literature review examines emerging clinical strategies to improve NRT efficacy. After an initial overview of NRT and its FDA-approved indications for use, we review randomized trials in which clinical delivery of NRT was manipulated and tested, in an attempt to enhance efficacy, through (1) duration of use (pre-quit and extended use), (2) amount of use (high-dose and combination NRT), (3) tailoring to specific smoker groups (genotype and phenotype), or (4) use of NRT for novel purposes (relapse prevention, temporary abstinence, cessation induction). Outcomes vary within and across topic area, and we highlight areas that offer stronger promise. Combination NRT likely represents the most promising strategy moving forward; other clinical strategies offer conflicting evidence but deserve further testing (pre-quit NRT or tailored treatment) or offer potential utility but are in need of further, direct tests. Some areas, though based on a limited set of studies, do not offer great promise (high-dose and extended treatment NRT). We conclude with a brief discussion of emergent NRT products (e.g., oral nicotine spray, among others), which may ultimately offer greater efficacy than current formulations. In order to further lower the prevalence of smoking, novel strategies designed to optimize NRT efficacy are needed.
Literature
1.
USDHS. State-specific prevalence and trends in adult cigarette smoking—United States, 1998–2007. MMWR. 2009;58:221–6.
2.
USDHS. Current cigarette smoking among adults—United States, 2011. MMWR. 2012;61:889–94.
3.
Méndez D, Alshanqeety O, Warner KE. The potential impact of smoking control policies on future global smoking trends. Tob Control. 2013;22:46–51.PubMedCrossRef
4.
USDHS. Cigarette smoking among adults—United States, 2007. MMWR. 2008;57:1221–6.
5.
USDHS. Quitting smoking among adults—United States, 2001–2010. MMWR. 2011;60:1513–9.
6.
Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med. 2005;28:119–22.PubMedCrossRef
7.
Ryan KK, Garrett-Mayer E, Alberg AJ, Cartmell KB, Carpenter MJ. Predictors of cessation pharmacotherapy use among African American and non-Hispanic white smokers. Nicotine Tob Res. 2011;13:646–52.PubMedCrossRef
8.
Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Individual differences in adoption of treatment for smoking cessation: demographic and smoking history characteristics. Drug Alcohol Depend. 2008;93:121–31.PubMedCrossRef
9.
Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34:102–11.PubMedCrossRef
10.
Fix BV, Hyland A, Rivard C, McNeill A, Fong GT, Borland R, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health. 2011;8(1):222–33.PubMedCrossRef
11.
Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res. 2011;13:793–9.PubMedCrossRef
12.
Amodei N, Lamb RJ. Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced? Psychol Addict Behav. 2008;22:472–85.PubMedCrossRef
13.
Carpenter MJ, Alberg AJ, Gray KM, Saladin ME. Motivating the unmotivated for health behavior change: a randomized trial of cessation induction for smokers. Clin Trials. 2010;7:157–66.PubMedCrossRef
14.
Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Arch Intern Med. 2011;171:1901–7.PubMedCrossRef
15.
Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol. 2004;72:371–81.PubMedCrossRef
16.
Giardina TD, Hyland A, Bauer UE, Cummings KM. Which population-based interventions would motivate smokers to think seriously about stopping smoking? Am J Health Promot. 2004;18:405–8.PubMedCrossRef
17.
Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8:739–49.PubMedCrossRef
18.
Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville: US Public Health Service; 2008.
19.
Zwar N, Richmond R, Borland R, Peters M, Litt J, Bell J, et al. Supporting smoking cessation: a guide for health professionals. The Royal Australian College of General Practitioners, Melbourne; 2011.
20.
21.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91.PubMedCrossRef
22.
Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, et al. A multicentre, randomised, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med. 2003;254:184–92.PubMedCrossRef
23.
Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation. Arch Intern Med. 2004;164:1797–803.PubMedCrossRef
24.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4 beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.PubMedCrossRef
25.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.PubMedCrossRef
26.
David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007;9(8):821–33.PubMedCrossRef
27.
Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11:234–9.PubMedCrossRef
28.
Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009;31:463–91.PubMedCrossRef
29.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–9.PubMedCrossRef
30.
Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation (Cochrane Review). Cochrane Database Syst Rev. 2008.
31.
Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, et al. Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program. Drug Alcohol Depend. 2010;107:237–43.PubMedCrossRef
32.
Hammond D, Reid JL, Driezen P, Cummings KM, Borland R, Fong GT, et al. Smokers’ use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC Four Country Survey. Addiction. 2008;103(10):1696–703.PubMedCrossRef
33.
Langley TE, Huang Y, Lewis S, McNeill A, Coleman T, Szatkowski L. Prescribing of nicotine replacement therapy to adolescents in England. Addiction. 2011;106:1513–9.PubMedCrossRef
34.
Shahab L, Cummings KM, Hammond D, Borland R, West R, McNeill A. The impact of changing nicotine replacement therapy licensing laws in the United Kingdom: findings from the International Tobacco Control Four Country Survey. Addiction. 2009;104:1420–7.PubMedCrossRef
35.
McNeil A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction. 2001;96:1757–68.CrossRef
36.
Shiffman S, Hughes JR. Improving on the proven: increased efficacy and reach with innovations in use of therapeutic nicotine. J Smok Cessat. 2009;4(Suppl 2):1–21.
37.
Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15:453–67.PubMedCrossRef
38.
Ingersoll KS, Cohen J. Combination treatment for nicotine dependence: state of the science. Subst Use Misuse. 2005;40:1923–2048.PubMedCrossRef
39.
Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc. 2008;48(5):659–65.CrossRef
40.
Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy (Review). The Cochrane Library 2009, Issue 9. Oxford: Wiley; 2009.
41.
Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy (Review). The Cochrane Library 2012, Issue 9. Oxford: Wiley; 2012.
42.
Grimshaw G, Stanton A. Tobacco cessation interventions for young people (Review). Cochrane Library 2010, Issue 1. Oxford: Wiley; 2010.
43.
Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatr Drugs. 2012;14(2):91–108.PubMedCrossRef
44.
Molyneux A, Lewis S, Lewis S, Leivers U, Anderton A, Antoniak M, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax. 2003;58:484–8.PubMedCrossRef
45.
Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: Issues and recommendations. Nicotine Tob Res. 2003;5:13–25.PubMed
46.
Hughes JR, Carpenter MJ, Naud S. Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review. Nicotine Tob Res. 2010;12:756–62.PubMedCrossRef
47.
Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerström K. Nicotine gum, 2 and 4 mg, for nicotine dependence: a double-blind placebo-controlled trial within a behavior modification support program. Chest. 1995;108:447–51.PubMedCrossRef
48.
Bullen C, Howe C, Lin R-B, Grigg M, Laugesen M, McRobbie H, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction. 2010;105:1474–83.PubMedCrossRef
49.
Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction. 2004;99:634–40.PubMedCrossRef
50.
Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res. 2006;8:89–101.PubMedCrossRef
51.
Rose JE, Herskovic JE, Behm FM, Westman EC. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Nicotine Tob Res. 2009;11:1067–75.PubMedCrossRef
52.
Rezaishiraz H, Hyland A, Mahoney MC, O’Connor RJ, Cummings KM. Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings. Nicotine Tob Res. 2007;9:1139–46.PubMedCrossRef
53.
Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998;6(3):331–43.PubMedCrossRef
54.
Etter JF, Huguelet P, Perneger TV, Cornuz J. Nicotine gum treatment before smoking cessation: a randomized trial. Arch Intern Med. 2009;169(11):1028–34.PubMedCrossRef
55.
56.
Hughes JR. Craving among long-abstinent smokers: an internet survey. Nicotine Tob Res. 2010;12:459–62.PubMedCrossRef
57.
Hughes JR, Keely JP, Naud S. Shape of relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29–38.PubMedCrossRef
58.
Hughes JR, Gust SW, Keenan R, Fenwick JW, Skoog K, Higgins ST. Long-term use of nicotine vs placebo gum. Arch Intern Med. 1991;151(10):1993–8.PubMedCrossRef
59.
Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. Transdermal nicotine for smoking cessation in postmenopausal women. Addict Behav. 2007;32(2):296–309.PubMedCrossRef
60.
Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med. 1993;153(16):1881–90.PubMedCrossRef
61.
Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269(10):1268–71.PubMedCrossRef
62.
Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995;90(1):31–42.PubMedCrossRef
63.
Pomerleau OF, Pomerleau CS, Marks JL, Snedecor SM, Mehringer AM, Namenek Brouwer RJ, et al. Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. J Subst Abuse Treat. 2003;24(1):13–8.PubMedCrossRef
64.
Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010;152:144–51.PubMedCrossRef
65.
Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13(2):238–46.PubMedCrossRef
66.
Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104:1043–52.PubMedCrossRef
67.
Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med. 2011;171:1894–900.PubMedCrossRef
68.
Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl). 2006;184:637–44.CrossRef
69.
Hatsukami DK, Mooney M, Murphy S, LeSage M, Babb D, Hecht S. Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol Biochem Behav. 2007;86:132–9.PubMedCrossRef
70.
Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol. 2006;74(6):1153–61.PubMedCrossRef
71.
Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. Nicotine Tob Res. 2013;15:348–54.PubMedCrossRef
72.
Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995;274(17):1353–8.PubMedCrossRef
73.
Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995;274(17):1347–52.PubMedCrossRef
74.
Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. J Subst Abuse Treat. 2006;30(3):213–7.PubMedCrossRef
75.
Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999;1(2):169–74.PubMedCrossRef
76.
Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol. 1999;7(3):226–33.PubMedCrossRef
77.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol Med. 2010;16(7–8):247–53.PubMed
78.
Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur Respir J. 1996;9(4):643–51.PubMedCrossRef
79.
Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. Cancer. 2005;55:281–99.
80.
Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl). 2003;166:343–50.
81.
Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248:1–17.PubMedCrossRef
82.
Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl). 1993;111(3):271–7.CrossRef
83.
Schneider NG, Cortner C, Gould JL, Koury MA, Olmstead R. Comparison of craving and withdrawal among four combination nicotine treatments. Hum Psychopharmacol Clin Exp. 2008;23:513–7.CrossRef
84.
Schneider NG, Cortner C, Justice M, Gould JL, Amor C, Hartman N, et al. Preferences among five nicotine treatments based on information versus sampling. Nicotine Tob Res. 2008;10:179–86.PubMedCrossRef
85.
Schneider NG, Koury MA, Cortner C, Olmstead RE, Hartman N, Kleinman L, et al. Preferences among four combination nicotine treatments. Psychopharmacology (Berl). 2006;187(4):476–85.CrossRef
86.
Perkins KA, Lerman C, Keenan J, Fonte C, Coddington S. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers. Nicotine Tob Res. 2004;6:501–7.PubMedCrossRef
87.
Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. Thorax. 2002;57:715–8.PubMedCrossRef
88.
Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med. 2009;150:447–54.PubMedCrossRef
89.
Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253–62.PubMedCrossRef
90.
Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of five smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;14:2148–55.CrossRef
91.
Bolt DM, Piper ME, Theobald WE, Baker TB. Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol. 2012;80(1):54–65.PubMedCrossRef
92.
Puska P, Korhonen HJ, Vartiainen V, Urjanheimo E, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control. 1995;4:231–5.CrossRef
93.
Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24(1):41–7.PubMedCrossRef
94.
Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction. 2009;104(9):1588–96.PubMedCrossRef
95.
Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ. 1999;318:285–8.PubMedCrossRef
96.
Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res. 2003;5:181–7.PubMedCrossRef
97.
Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2000;160(20):3128–34.PubMedCrossRef
98.
Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J. 2000;16(4):717–22.PubMedCrossRef
99.
Kalman D, Tirch D, Kahler C, Penk W, Kaschub C, Monti PM. Twelve-week outcomes from an investigation of high dose nicotine patch therapy for heavy smokers with a past history of alcohol dependence. Psychol Addict Behav. 2004;18:78–82.PubMedCrossRef
100.
West R, Hajek P, Foulds J, Nilsson F, Burrows S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 2000;149:198–202.CrossRef
101.
Benowitz NL. Nicotine safety and toxicity. New York: Oxford University Press; 1998.
102.
Hughes JR, Pillitteri JL, Callas PW, Calahan R, Kenny M. Misuse of and dependence on over-the-counter nicotine gum in a volunteer sample. Nicotine Tob Res. 2004;6:79–84.PubMedCrossRef
103.
Yudkin PL, Jones L, Lancaster T, Fowler GH. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial. Br J Gen Pract. 1996;46(404):145–8.PubMed
104.
Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989;12(2):159–82.PubMedCrossRef
105.
Kortmann GL, Dobler CJ, Bizarro L, Bau CH. Pharmacogenetics of smoking cessation therapy. Am J Med Genet. 2010;153B(1):17–28.PubMed
106.
Lerman CE, Schnoll RA, Munafò MR. Genetics and smoking cessation: improving outcomes in smokers at risk. Am J Prev Med. 2007;33:S398–405.PubMedCrossRef
107.
Munafo MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res. 2011;13(10):982–8.PubMedCrossRef
108.
Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuropsychopharmacology. 2012;37:1683–8.PubMedCrossRef
109.
Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1312–4.PubMedCrossRef
110.
Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B, et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res. 2000;2:53–63.PubMedCrossRef
111.
Niaura R, Goldstein MG, Abrams DB. Matching high- and low-dependence smokers to self-help treatment with or without nicotine replacement. Prev Med. 1994;23(1):70–7.PubMedCrossRef
112.
Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer H, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med. 1988;318(1):15–8.PubMedCrossRef
113.
Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92:6–11.PubMedCrossRef
114.
Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600–8.PubMedCrossRef
115.
Marteau TM, Aveyard P, Munafo MR, Prevost AT, Hollands GJ, Armstrong D, et al. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. PLoS ONE. 2012;7(4):e35249.PubMedCrossRef
116.
Abrams DB, Orleans CT, Niaura RS, Goldstein MG, Prochaska JO, Velicer W. Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: a combined stepped-care and matching model. Ann Behav Med. 1996;18:290–304.PubMedCrossRef
117.
Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB. The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol. 2011;79:34–42.PubMedCrossRef
118.
Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74(2):276–85.PubMedCrossRef
119.
Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl). 2006;184(3–4):608–18.CrossRef
120.
Agboola S, McNeill A, Coleman T, Bee JL. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362–80.PubMedCrossRef
121.
Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation (Review). The Cochrane Library 2009.
122.
Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102:1292–302.PubMedCrossRef
123.
Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007;82(2):186–95.PubMed
124.
Fortmann SP, Killen JD. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. J Consult Clin Psychol. 1995;63(3):460–8.PubMedCrossRef
125.
Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol. 1990;60:586–94.
126.
Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. J Subst Abuse Treat. 2003;24(3):251–5.PubMedCrossRef
127.
Schroter M, Collins SE, Frittrang T, Buchkremer G, Batra A. Randomized controlled trial of relapse prevention and a standard behavioral intervention with adult smokers. Addict Behav. 2006;31(7):1259–64.PubMedCrossRef
128.
Stein MD, Anderson BJ, Niaura R. Nicotine replacement therapy: patterns of use after a quit attempt among methadone-maintained smokers. J Gen Intern Med. 2006;21(7):753–7.PubMedCrossRef
129.
Wetter DW, McClure JB, Cofta-Woerpel L, Costello TJ, Reitzel LR, Businelle MS, et al. A randomized clinical trial of a palmtop computer-delivered treatment for smoking relapse prevention among women. Psychol Addict Behav. 2011;25(2):365–71.PubMedCrossRef
130.
Shiffman S, Khayrallah M, Nowak R. Efficacy of the nicotine patch for relief of craving and withdrawal 7–10 weeks after cessation. Nicotine Tob Res. 2000;2:371–8.PubMedCrossRef
131.
Tiffany S, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol. 2000;68:233–40.PubMedCrossRef
132.
Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol. 2004;72:1136–43.PubMedCrossRef
133.
Foulds J. Use of nicotine replacement therapy to treat nicotine withdrawal syndrome and aid temporary abstinence. Int J Clin Pract. 2010;64:292–4.PubMedCrossRef
134.
Schmidt CW. A change in the air: smoking bans gain momentum worldwide. Environ Health Perspect. 2007;115:A412–5.PubMedCrossRef
135.
Borland R, Yong HH, Cummings KM, Hyland A, Anderson S, Fong GT. Determinants and consequences of smoke-free homes: findings from the International Tobacco Control (ITC) Four Country Survey. Tob Control. 2006;15(Suppl 3):iii42–50.PubMedCrossRef
136.
137.
138.
USDHS. The health consequences of involuntary exposure to tobacco smoke: a report of the surgeon general. Washington DC: US Govt. Printing Office; 2006.
139.
Jones TE, Williams J. Craving control using nicotine replacement therapy in a teaching hospital. Intern Med. 2012;42:317–22.CrossRef
140.
Levy DE, Thorndike AN, Biener L, Rigotti NA. Use of nicotine replacement therapy to reduce or delay smoking but not to quit: prevalence and association with subsequent cessation efforts. Tob Control. 2007;16(6):384–9.PubMedCrossRef
141.
Beard E, West R. Use of nicotine replacement therapy for smoking reduction and temporary abstinence: an update of Beard et al. (2011). Addiction. 2012;107:1186–7.PubMedCrossRef
142.
Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R. Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction. 2011;106:197–204.PubMedCrossRef
143.
144.
Wewers ME, Stillman FA, Hartman AM, Shopland DR. Distribution of daily smokers by stage of change: current population survey results. Prev Med. 2003;36:710–20.PubMedCrossRef
145.
Etter JF. Comparing abrupt and gradual smoking cessation: a randomized trial. Drug Alcohol Depend. 2011;118:360–5.PubMedCrossRef
146.
Hughes JR, Solomon LJ, Livingston AE, Callas PW, Peters EN. A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit. Drug Alcohol Depend. 2010;111:105–13.PubMedCrossRef
147.
Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized placebo-controlled study. Clin Pharmacol Ther. 2005;78:689–96.PubMedCrossRef
148.
Etter JF, Laszlo E. Postintervention effect of nicotine replacement therapy for smoking reduction: a randomized trial with a 5-year follow-up. J Clin Psychopharmacol. 2007;27:151–5.PubMedCrossRef
149.
Etter JF, Laszlo E, Perneger TV. Post-intervention effect of nicotine replacement therapy on smoking reduction in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol. 2004;24:174–9.PubMedCrossRef
150.
Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine Tob Res. 2006;8:555–64.PubMedCrossRef
151.
Wennike P, Danielsson T, Landeck BF, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation. Results from a double blind, randomised, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98:1395–402.PubMedCrossRef
152.
Carpenter MJ, Hughes JR, Keely JP. Effect of smoking reduction on later cessation: a pilot experimental study. Nicotine Tob Res. 2003;5:155–62.PubMedCrossRef
153.
Joseph AM, Hecht SS, Murphy SE, Lando H, Carmella SG, Gross M, et al. Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine Tob Res. 2008;10:471–81.PubMedCrossRef
154.
Tonnesen P, Pisinger C, Hvidberg S, Wennike P, Bremann L, Westin A, et al. Effects of smoking cessation and reduction in asthmatics. Nicotine Tob Res. 2005;7:139–48.PubMedCrossRef
155.
Chan SSC, Leung DYP, Abdullah ASM, Wong VT, Hedley AJ, Lam T-H. A randomised controlled trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not willing to quit smoking. Addiction. 2011;106(6):1155–63.PubMedCrossRef
156.
Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav. 2011;36:764–8.PubMedCrossRef
157.
Hatsukami DK, Perkins KA, Lesage MG, Ashley DL, Henningfield JE, Benowitz NL, et al. Nicotine reduction revisited: science and future directions. Tob Control. 2010;19(5):e1–10.PubMedCrossRef
158.
Hughes JR. Reduced smoking: an introduction and review of the evidence. Addiction. 2000;95:S3–8.PubMed
159.
Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction. 2005;100:1074–89.PubMedCrossRef
160.
Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use (Cochrane Review). The Cochrane Library, Issue 3. Oxford: Updated Software; 2007.
161.
Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. Br Med J. 2009;338:b1024.CrossRef
162.
Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess. 2008;12(2):iii–iv, ix–xi, 1–135.
163.
Fagerstrom K-O, Tejding R, Ake W, Lunell E. Aiding reduction of smoking with nicotine replacement medications. Hope for the recalcitrant smoker? Tob Control. 1997;6:311–6.PubMedCrossRef
164.
Jolicoeur DG, Richter KP, Ahluwalia JS, Mosier MC, Resnicow K. Smoking cessation, smoking reduction, and delayed quitting among smokers given nicotine patches and a self-help pamphlet. Subst Abuse. 2003;24:101–6.
165.
Shahab L, McEwen A, West R. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial. Psychopharmacology (Berl). 2011;216:187–96.CrossRef
166.
Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol. 2010;18:385–94.PubMedCrossRef
167.
Thornley S, McRobbie H, Lin R, Bullen C, Hajek P, Laugesen M, et al. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Res. 2009;11:715–21.PubMedCrossRef
168.
Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, et al. Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav. 2009;91:380–4.PubMedCrossRef
169.
Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open. 2012;2:e001618.PubMedCrossRef
170.
McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, et al. A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction. 2010;105(7):1290–8.PubMedCrossRef
171.
Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J. 2012;40:548–54.PubMedCrossRef
172.
Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74:196–201.PubMedCrossRef
173.
Hughes JR, Adams EH, Franzon MA, Maguire MK, Guary J. A prospective study of off-label use of, abuse of and dependence on nicotine inhaler. Tob Control. 2005;14:49–54.PubMedCrossRef
Metadata
Title
Clinical Strategies to Enhance the Efficacy of Nicotine Replacement Therapy for Smoking Cessation: A Review of the Literature
Authors
Matthew J. Carpenter
Bianca F. Jardin
Jessica L. Burris
Amanda R. Mathew
Robert A. Schnoll
Nancy A. Rigotti
K. Michael Cummings
Publication date
01-04-2013
Publisher
Springer International Publishing AG
Published in
Drugs / Issue 5/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0038-y

Other articles of this Issue 5/2013

Drugs 5/2013 Go to the issue

R&D Insight Report

Mipomersen Sodium: First Global Approval

Adis Drug Evaluation

Lorcaserin: A Review of its Use in Chronic Weight Management

Review Article

Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions

Leading Article

Multifocal Motor Neuropathy: Current Therapies and Novel Strategies

Editorial

Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin?

Adis Drug Evaluation

Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer